7 mistakes that companies make when translating medical or technical content
Localisation of medical or technical content is not a formatting task; it is a risk-management process. When companies treat it as a late, low-cost or automated step, they increase the chances of errors that can affect approvals, safety, credibility and business performance in regulated markets. In sectors such as pharma, medical devices, engineering, energy, fintech and defence, translated content is often read by people who must act on it: clinicians, patients, regulators, technicians, legal teams and buyers. A mistranslated instruction, inconsistent term or unvalidated AI output can create consequences far beyond awkward wording. The seven mistakes below are common because they look efficient at first. In practice, they often create rework, delays and exposure that could have been avoided with the right process from the beginning. 1. Why is treating translation as an afterthought so risky? The first mistake is leaving Localisation planning until the end of the content workflow. By then, the source text may already be approved, designed, locked in complex formats or distributed across several teams and platforms. This creates avoidable pressure. Translators and reviewers are asked to deliver faster, with less context and fewer opportunities to ask questions. In regulated industries, that is exactly when small inconsistencies can become serious quality issues. Translation should be planned from day one, especially when content will support product approvals, patient information, technical operations or contractual commitments. Early involvement allows terminology, reference materials, workflows and review responsibilities to be defined before deadlines become critical. A better approach starts with questions such as: Which markets, languages and regulatory contexts are involved? Who will approve the translated content internally? Which terms must remain consistent across documents? Which files, formats and platforms will be used? What is the acceptable review and validation process? When translation is integrated early, teams reduce last-minute decisions and protect both quality and time-to-market. 2. What happens when companies choose providers based on price alone? The second mistake is treating the lowest quote as the safest business decision. In complex medical or technical content, price-only selection often hides the real cost of poor quality. A cheaper supplier may lack specialist linguists, structured quality assurance, terminology controls or experience with regulated documentation. The result can be rework, internal escalation, delayed approvals and loss of confidence among stakeholders. This does not mean that cost is irrelevant. It means cost must be assessed alongside risk, expertise, process and accountability. Translation for a brochure, an internal memo and a regulated product document should not be bought as if they carried the same consequences. Companies should evaluate providers on practical criteria: Proven experience in medical, technical or regulated content Clear quality assurance and review stages Ability to manage terminology and reference materials Secure handling of confidential documentation Responsiveness when questions or deviations arise The right question is not “Which supplier is cheapest?” but “Which supplier reduces the risk of error, delay and non-compliance?” 3. Why does subject-matter expertise matter so much? The third mistake is assuming that fluency in two languages is enough. It is not. Medical and technical translation requires subject-matter expertise, because the translator must understand both the language and the content logic behind it. A generalist may produce text that sounds natural but fails technically. In regulated communication, that is especially dangerous because the error may be subtle: a dose, device component, procedural step, claim, limitation or warning may be expressed in a way that changes its meaning. Medical translation requires control of terminology, patient safety implications, document conventions and the difference between technical precision and plain-language clarity. Technical translation requires understanding of systems, processes, components, operating conditions and the practical consequences of ambiguous instructions. Regulated-sector translation requires awareness that every word may be reviewed, queried or relied upon by a professional, auditor, regulator or end user. Subject-matter expertise also improves collaboration. Specialist translators know when to ask a question, when a term should not be “improved”, and when consistency matters more than stylistic variation. In regulated content, a translation is not successful because it reads well; it is successful because the right reader can act on it safely and correctly. 4. How does inconsistent terminology create compliance problems? The fourth mistake is allowing different terms for the same concept to appear across related documents. Terminology consistency is not a cosmetic preference; it is a core quality requirement. If one document uses one term, another uses a near-synonym and a third uses an internal abbreviation, readers may wonder whether the content refers to the same concept or to different ones. In technical and medical contexts, that uncertainty can affect interpretation, training, reporting and regulatory review. Terminology management helps prevent this. It gives translators and reviewers an approved reference point for critical terms, product names, procedures, warnings, component labels and recurring phrases. Good terminology work typically includes: Approved glossaries for key terms and expressions Clear rules for product names, abbreviations and units Alignment across departments and document types Updates when source terminology changes Reuse of validated terms in future projects The benefit is cumulative. Each approved term strengthens future work, reduces review cycles and protects consistency across markets. 5. Can AI translate medical and technical content safely? The fifth mistake is over-relying on AI without expert human validation. AI can be useful for scalability, drafting and workflow support, but human validation remains critical where accuracy, liability and compliance are involved. AI systems can produce fluent output that looks convincing even when it is wrong. That is a particular risk in medical and technical content, where errors may not be obvious to a non-specialist reviewer. A sentence can sound polished while misrepresenting a procedure, caution, limitation or technical relationship. The question is not whether AI should ever be used. The question is where it fits safely inside a controlled process. In regulated content, machine-assisted workflows need expert review, terminology control, confidentiality safeguards and clear responsibility for final approval. Companies should be cautious when AI is used for: Patient-facing information or instructions Clinical, legal or regulatory documentation Safety warnings and adverse-event language Technical